Prime Sciences FDA Warning Letter: Letter 721805

Updated August 23, 2026

Prime Sciences of Scottsdale, Arizona received FDA warning letter 721805, dated March 31, 2026 and posted to the agency's public index on April 7, 2026 — one of seven letters issued to research-peptide sellers on the same date. It is a different entity from Prime Vitality Inc dba Prime Peptides, a December 2024 letter recipient.

Letter record

Not Prime Peptides: two recipients, two batches

Two FDA letter recipients in this record carry the word "Prime," and secondary coverage sometimes runs them together. They are separate entries. Prime Sciences, the subject of this page, is the Scottsdale, Arizona recipient of letter 721805 in the March 2026 batch. Prime Vitality Inc dba Prime Peptides received letter 695156-12102024 in the December 2024 batch, roughly fifteen months earlier. Nothing in the verified record connects the two companies; the shared word is the whole overlap. The side-by-side record is kept at Prime Peptides and Prime Sciences: two different FDA letter recipients.

What the batch documents

The seven letters of March 31, 2026 return to two findings. First, product pages describing therapeutic effects of the compounds — language about what a compound does in a human subject, sitting beside research-use-only labeling. Second, administration supplies offered in the same cart as the compounds; in the letters, the makeup of the checkout stands as evidence of intended use in its own right. Regulatory coverage of the batch also records coded product listings — "GLP-1 SM" and "GLP-3 RT" are the documented examples — which the agency read as circumvention rather than caution. Those coded names are batch-level examples; this index does not attribute them to any single recipient. By recipient count, the seven-letter action is the largest single-date warning-letter batch against research-peptide sellers in this index's record; the December 10, 2024 action, the one that reached Prime Peptides, named four entities.

The agency's position on disclaimers

The batch answers the research-use-only question in the agency's own words: despite the disclaimers, "evidence obtained from your website establishes that your products are intended to be drugs for human use." The letters do not record any recipient's response, and this index makes no claim about what Prime Sciences did after receipt.

Locating the letter

This index has not captured a confirmed direct URL for letter 721805, so none is printed here and none is guessed. The letter is retrievable from FDA's public warning-letters database by searching the recipient name; that database is the citation under Sources. The batch it belongs to is documented at FDA warning letters of March 31, 2026, and the recipient's entry sits in the vendor index alongside the other six.

Sources

1. FDA Warning Letters index (retrieves the Prime Sciences letter, 721805, by recipient name). fda.gov
2. Policy Canary analysis of the March 31, 2026 batch. policycanary.io
3. Partnership for Safe Medicines, PDF summary of the seven letters (April 7, 2026 posting). safemedicines.org

How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.